Genmab A/S Stock Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
00:00:00 31/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 57.06 USD | +1.01% |
|
+30.30% | +85.26% |
| 10-30 | AlphaValue/Baader Europe Upgrades Genmab to Reduce | MT |
| 10-29 | Deutsche Bank raises price target for Genmab to DKK 4,000 (3,500), reiterates buy - BN | FW |
| Market Cap | 234B 34.92B 31.27B 28.76B 26.06B 48.72B 3,315B 49.63B 343B 138B 1,744B 131B 128B 5,500B | P/E 2026 * |
47.3x | P/E 2027 * | 32.7x |
|---|---|---|---|---|---|
| Enterprise Value | 254B 37.88B 33.93B 31.21B 28.28B 52.85B 3,597B 53.84B 372B 149B 1,892B 142B 139B 5,967B | EV / Sales 2026 * |
8.41x | EV / Sales 2027 * | 6.77x |
| Free-Float |
94.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| GMAB | Delayed | |
CBOE
| GMAB | Real-time | |
|
Boerse Muenchen
| GE91 | Real-time | |
|
Tradegate
| GE91 | Real-time | |
|
Börse Stuttgart
| GE91 | Delayed | |
|
Deutsche Boerse AG
| GE91 | Delayed |
Last Transcript: Genmab A/S
| 1 day | +1.01% | ||
| 1 week | +30.30% | ||
| Current month | +59.94% | ||
| 1 month | +59.94% | ||
| 3 months | +99.23% | ||
| 6 months | +115.16% | ||
| Current year | +85.26% |
| 1 week | 43.98 |  | 59.97 |
| 1 month | 33.72 | | 59.97 |
| Current year | 23.62 | | 59.97 |
| 1 year | 23.62 | | 59.97 |
| 3 years | 17.24 | | 59.97 |
| 5 years | 17.24 | | 59.97 |
| 10 years | 12.1 | | 59.97 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 75 | 01/01/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.01% | +30.30% | - | - | 34.92B | |
| -0.62% | -1.87% | +46.31% | +56.99% | 63.77B | |
| +0.35% | +3.20% | +14.92% | +84.55% | 56.37B | |
| +0.53% | +1.96% | +15.37% | +106.81% | 54.62B | |
| -2.81% | -4.31% | +23.50% | +50.90% | 44.06B | |
| -0.33% | -1.93% | +20.15% | +98.45% | 42.11B | |
| +0.55% | +2.31% | +224.97% | +942.56% | 41B | |
| +3.27% | +47.96% | +112.67% | +96.48% | 34.92B | |
| +1.22% | -1.44% | +14.89% | +47.15% | 32.82B | |
| +0.89% | +20.55% | -42.03% | +373.03% | 24.7B | |
| Average | +0.41% | +7.54% | +47.86% | +206.32% | 43.82B | |
| Weighted average by Cap. | +0.25% | +5.44% | +48.50% | +186.13% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.15B 4.5B 4.03B 3.71B 3.36B 6.28B 428B 6.4B 44.24B 17.76B 225B 16.9B 16.54B 709B | 36.29B 5.42B 4.85B 4.47B 4.05B 7.56B 515B 7.7B 53.25B 21.38B 271B 20.34B 19.91B 854B |
| Net income | 5.14B 768M 687M 632M 573M 1.07B 72.88B 1.09B 7.54B 3.03B 38.33B 2.88B 2.82B 121B | 7.6B 1.14B 1.02B 935M 847M 1.58B 108B 1.61B 11.15B 4.48B 56.7B 4.26B 4.17B 179B |
| Net Debt | 19.85B 2.96B 2.66B 2.44B 2.21B 4.14B 281B 4.21B 29.13B 11.69B 148B 11.13B 10.89B 467B | 11.9B 1.78B 1.59B 1.46B 1.33B 2.48B 169B 2.53B 17.46B 7.01B 88.75B 6.67B 6.53B 280B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | $57.06 | +1.01% | 8,649,171 |
| 29/10/26 | $56.49 | -1.40% | 6,253,144 |
| 28/10/26 | $57.29 | +28.25% | 29,283,870 |
| 27/10/26 | $44.67 | -0.03% | 4,929,100 |
| 26/10/26 | $44.69 | +2.04% | 7,473,717 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
